Nieuws en video's - MOTIF BIO ORD 0.01P

U bekijkt momenteel alle beurs nieuws van het financieel instrument MOTIF BIO ORD 0.01P over alle markten in alle talen.

MOTIF BIO ORD 0.01P > Nieuws Tip TV Finance heeft een nieuwe video gepubliceerd.

Master Investor: Iclaprim is lead hospital infection-fighting antibiotic - Motif Bio • • Tip TV Finance • Aandelen

Graham Lumsden, CEO of Motiff Bio, talks about Iclaprim - a novel drug that is proving to be effective against drug resistant bacteria and hospital infections....

Dank u

MOTIF BIO ORD 0.01P > Nieuws GlobeNewsWire heeft een nieuws gepubliceerd.

Motif Bio Phase 3 Clinical Trial Finishes Patient Treatment Phase • • GlobeNewsWire • Aandelen

NEW YORK, Jan. 30, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced that the last patient has finished the treatment phase in REVIVE-1, the Phase 3 clinical trial investigating the safety and efficacy of iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI). REVIVE-1 is a 600-patient double-blinded, global, multicenter trial, in...

Dank u

MOTIF BIO ORD 0.01P > Nieuws GlobeNewsWire heeft een nieuws gepubliceerd.

Motif Bio plc Announces Conversion of Convertible Promissory Notes, PDMR Dealing and Total Voting Rights • • GlobeNewsWire • Aandelen

NEW YORK, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, announced that it has issued, in aggregate, 14,510,770 new ordinary shares in the Company ("Ordinary Shares") following the conversion by Amphion Innovations plc and Amphion Innovations US Inc., (the “Amphion Parties”) of the Convertible Promissory Notes (“CPNs”). The CPNs which totalled US$3,550,786 were...

Dank u

MOTIF BIO ORD 0.01P > Nieuws GlobeNewsWire heeft een nieuws gepubliceerd.

Motif Bio plc Announces Closing of its $25 Million U.S. Initial Public Offering and European Placement • • GlobeNewsWire • Aandelen

NEW YORK, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif) (NASDAQ:MTFB), (NASDAQ:MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, announced today the closing of its initial U.S. public offering of approximately 2.44 million American Depositary Shares (ADSs) with 50% warrant coverage. Each ADS, representing 20 ordinary shares of Motif, and warrant to purchase 0.5 ADSs were sold at a price to the public of $6.98 per ADS and warrant...

Dank u

MOTIF BIO ORD 0.01P > Nieuws GlobeNewsWire heeft een nieuws gepubliceerd.

Motif Bio plc Announces Pricing Of $25 Million U.S. Initial Public Offering and European Placing • • GlobeNewsWire • Aandelen

NEW YORK, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Motif Bio plc (Motif)(NASDAQ:MTFB), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced the pricing of its initial public offering in the United States of approximately 2.44 million American Depositary Shares (ADSs) with 50% warrant coverage. Each ADS, representing 20 ordinary shares of Motif, and warrant to purchase 0.5 ADSs are being offered at an offering price to the public of $6.98 per ADS and...

Dank u